February’s roundup of articles features stories on India’s drug standards, CRISPR gene editing, new drugs for pain management, depression, and overdosing, Obama’s Precision Medicine Initiative, and a new, major study on the link between Zika virus and birth defects.
Have a perspective on one of these stories? Submit your post to the AAPS Blog!
- “Obama Is Using the Bully Pulpit to Set Patient Data Free,” by Matthew Herper, Forbes, February 25, 2016
- “Whoops! 12 Tales of Accidental Brilliance In Science,” by Adam Cole, NPR, February 24, 2016
- “CDC, Brazil Start Big Study to Test Zika Link to Birth Defects,” by Julie Steenhuysen, Scientific American, February 22, 2016
- “The Ibuprofen Inventor,” by Julia Robinson, The Pharmaceutical Journal, February 22, 2016
- “The Effects of the Trans-Pacific Partnership on Pharmaceutical Innovation,” Elsevier, January 22, 2016
- “One In Every Seven Indian Drugs Is Below Standard. Is Health Minister Listening?” Indiatimes, February 18, 2016
- “Walgreens to Sell Naloxone, Heroin, and Prescription Pain Med Overdose Antidote, over the Counter,” by Susan Scutti, Medical Daily, February 10, 2016
- “CRISPR, but No Clearer about the Human Embryo,” by Javier Cuadros, Mercatornet February 9, 2016
- “This New Drug is as Strong as Morphine, but without the Side Effects,” by Peter Dockrill, Science Alert, February 1, 2016
- “Onetime Party Drug Hailed as Miracle for Treating Severe Depression,” by Sara Solovitch, The Washington Post, February 1, 2016
- “How to Give a C-section Baby the Potential Benefits of Vaginal Birth,” by Jennifer Couzin-Frankel, Science, February 1, 2016